Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirolimus albumin bound - Abraxis Bioscience

Next Previous
Drug Profile

Sirolimus albumin bound - Abraxis Bioscience

Alternative Names: ABI-009; albumin-bound rapamycin; FYARRO; Nab-rapamycin; Nab-sirolimus; TARZIFYX

Latest Information Update: 02 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abraxis BioScience
  • Developer Children's Oncology Group; Mirati Therapeutics; National Cancer Institute (USA); Ochsner Clinic Foundation; Seattle Children's Hospital; University of Washington; Whitehawk Therapeutics
  • Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Perivascular epithelioid cell tumours
  • New Molecular Entity No

Highest Development Phases

  • Marketed Perivascular epithelioid cell tumours
  • Phase II Endometrial cancer; Glioblastoma; Glioma; Leigh disease; Neuroendocrine tumours; Solid tumours
  • Phase I/II Bladder cancer; Colorectal cancer; Sarcoma; Soft tissue sarcoma
  • Phase I Epilepsy; Non-small cell lung cancer; Pulmonary arterial hypertension

Most Recent Events

  • 18 Mar 2025 Aadi Bioscience is now called Whitehawk Therapeutics
  • 23 May 2024 Pharmacodynamics data from preclinical study in Solid tumours released by Aadi Bioscience
  • 08 May 2024 Aadi Bioscience terminates its collaboration agreement with Mirati Therapeutics to evaluate the combination of adagrasib and nab-sirolimus before May 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top